Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CpG oligodeoxynucleotide B344 (CpG B344) is a synthetic, single-stranded DNA molecule containing unmethylated cytosine-guanine (CpG) motifs, specifically categorized as a Class B CpG ODN. It functions as a potent agonist of Toll-like receptor 9 (TLR9), an endosomal receptor that recognizes pathogen-associated molecular patterns (PAMPs) in the form of DNA. Upon activation, CpG B344 triggers a signaling cascade involving the adapter protein MyD88 and the NF-κB pathway, leading to the maturation of antigen-presenting cells and the secretion of pro-inflammatory cytokines such as IL-12 and IFN-γ. While CpG ODNs are broadly studied across species, the B344 sequence (typically an 18-mer consisting of TCG repeats) is particularly prominent in veterinary research. It is utilized as an immunomodulator and vaccine adjuvant to enhance protective immunity against avian pathogens, including avian influenza virus, *Salmonella enteritidis*, and infectious bursal disease virus.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on CpG oligodeoxynucleotide B344.